3ZG-10773-14257
2 vaccinations
1 coded response
22 check-ins
1 free-text entry
1 call case
- Sex
- Female
- Age at first dose
- 0-4
- ZIP prefix
- 971 / OR
- Registered
- 2022-09-25
- Relationship
- Child or adolescent in my care
- Guardian
- XE5-11611-91228
- Race
- Multiracial
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2022-09-25
Registered in v-safe
-
2022-10-13
Dose 1 — Pfizer-BioNTechCo-administered: Flu:Hib:Polio:Rotavirus:Tetanus
- 2022-10-13
-
2022-10-14
Health check-in — days 1–6 daily, dose 1, under 3Feeling: Fair · Site: Redness · Fever · Sleepiness · Be unable to work or attend schoolUnder 3 check-in
-
2022-10-15
Health check-in — days 1–6 daily, dose 1, under 3Feeling: Fair · Site: Redness · Fever · Sleepiness, Irritability/crying · Be unable to work or attend schoolUnder 3 check-in
-
2022-10-16
Health check-in — days 1–6 daily, dose 1, under 3Feeling: Good · Site: Redness · NoneUnder 3 check-in
-
2022-10-17
Health check-in — days 1–6 daily, dose 1, under 3Feeling: Good · Site: Swelling/hardness · SleepinessUnder 3 check-in
-
2022-10-19
Health check-in — days 1–6 daily, dose 1, under 3Feeling: Good · Site: Swelling/hardness · NoneUnder 3 check-in
-
2022-10-20
Health check-in — day 7, dose 1, under 3Feeling: Good · Site: Swelling/hardness · Rash, not including the immediate area around the injection siteUnder 3 check-in
- 2022-10-27
-
2022-11-03
Dose 2 — Pfizer-BioNTech
-
2022-11-04
Health check-in — days 1–6 daily, dose 2, under 3Feeling: Good · Site: Pain, Swelling/hardness · SleepinessUnder 3 check-in
-
2022-11-05
Health check-in — days 1–6 daily, dose 2, under 3Feeling: Good · Site: Swelling/hardness · NoneUnder 3 check-in
-
2022-11-06
Health check-in — days 1–6 daily, dose 2, under 3Feeling: Fair · Site: Swelling/hardness · Irritability/cryingUnder 3 check-in
- 2022-11-07
- 2022-11-08
- 2022-11-09
- 2022-11-11
- 2022-11-17
-
2022-11-24
Survey response — day 21, dose 2, under 3MedDRA: Cough, Irritability, Pyrexia, Rhinorrhoea, Sneezing, Upper respiratory tract infection — Feeling: Fair · Be unable to work or attend school, Get care from a doctor or other healthcare professional · Emergency room or emergency department visitFree text: Upper respiratory infection, possibly RSV, with symptoms like coughing, sneezing, runny nose, irritability, and low grade feverMedDRA releases: 2024-11 · check-in free text available
-
2022-11-24
Report sent to call center — day 21, dose 2, under 3Be unable to work or attend school · Get care from a doctor or other healthcare professionalEmergency room or emergency department visit · 1 call case(s)
-
2022-11-25
Call successfulNot applicable – Participant does not believe symptoms are related to vaccine and does not wish to fill
- 2022-12-03
- 2022-12-08
- 2022-12-15
- 2023-02-02
- 2023-05-04
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2022-10-13 | Pfizer-BioNTech | Flu:Hib:Polio:Rotavirus:Tetanus |
| 2 | 2022-11-03 | Pfizer-BioNTech | No |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2022-11-24 | Successful 2022-11-25 |
Not applicable – Participant does not believe symptoms are related to vaccine and does not wish to fill |
Free text
Release 12 (Under 3) — day 21, dose 2, under 3
Symptoms: Upper respiratory infection, possibly RSV, with symptoms like coughing, sneezing, runny nose, irritability, and low grade fever
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Cough | · | · | ✓ |
| SD | Irritability | · | · | ✓ |
| SD | Pyrexia | · | · | ✓ |
| SD | Rhinorrhoea | · | · | ✓ |
| SD | Sneezing | · | · | ✓ |
| SD | Upper respiratory tract infection | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release